Zaniolo, O. et al. 2007. Budget impact of rosiglitazone in type 2 diabetes. Farmeconomia. Health economics and therapeutic pathways. 8, 1 (Mar. 2007), 15–26. DOI:https://doi.org/10.7175/fe.v8i1.252.